NANT 2019-01

NANT 2019-01: Phase 1 LY3295668 

Study: NANT 2019-01

Protocol Title: Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma

Protocol Chair: Dr. Stephen DuBois

For more information about this trial, visit clinicaltrials.gov